APA (7th ed.) Citation

M, M., M, F., AM, S., MJ, S., & A, N. (2024). A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 mg/day on Abdominal Symptoms and its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome. Clinical drug investigation, 44(11), 839. https://doi.org/10.1007/s40261-024-01403-w

Chicago Style (17th ed.) Citation

M, Mokhtare, Fathi M, Sadeghian AM, Sotoudeheian MJ, and Namazi A. "A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 Mg/day on Abdominal Symptoms and Its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome." Clinical Drug Investigation 44, no. 11 (2024): 839. https://doi.org/10.1007/s40261-024-01403-w.

MLA (9th ed.) Citation

M, Mokhtare, et al. "A Pilot Study of the Effectiveness of a Short Course of Rifaximin 2200 Mg/day on Abdominal Symptoms and Its Effects on Quality of Life in Patients with Moderate to Severe Diarrhea-Predominant Irritable Bowel Syndrome." Clinical Drug Investigation, vol. 44, no. 11, 2024, p. 839, https://doi.org/10.1007/s40261-024-01403-w.